2022
DOI: 10.1016/j.ekir.2022.03.030
|View full text |Cite
|
Sign up to set email alerts
|

Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
25
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(27 citation statements)
references
References 47 publications
0
25
0
Order By: Relevance
“…More recently, Schreeb et al. established a phase I/IIa study protocol (STEADFAST) to expand and infuse recipient HLA-A2 CAR-CD4 + /CD45RA + /CD25 + /CD127 low/neg Tregs into HLA-A2 negative end-stage renal disease recipients ( 188 ). Consistent with previous findings, infused HLA-A2 CAR-Tregs are anticipated to migrate to and bind to the specifically targeted HLA-A2 positive allograft.…”
Section: Foxp3+ Treg-based Therapies In Solid Organ Transplantationmentioning
confidence: 99%
“…More recently, Schreeb et al. established a phase I/IIa study protocol (STEADFAST) to expand and infuse recipient HLA-A2 CAR-CD4 + /CD45RA + /CD25 + /CD127 low/neg Tregs into HLA-A2 negative end-stage renal disease recipients ( 188 ). Consistent with previous findings, infused HLA-A2 CAR-Tregs are anticipated to migrate to and bind to the specifically targeted HLA-A2 positive allograft.…”
Section: Foxp3+ Treg-based Therapies In Solid Organ Transplantationmentioning
confidence: 99%
“…For example, the activity and interaction of chimeric antigen receptor-regulatory T cells (CAR-Treg), with cells of the host immune system. 6,7 In this edition of Transplantation, Ellis et al 8 propose a new model: human A2-CAR T cells as a tool to study T-cell-mediated rejection of human islets transplanted into mice without the complication of xGVHD. CARs are genetically engineered receptors that provide specific properties to immune cells including T cells, Treg, B cells, and natural killer cells.…”
mentioning
confidence: 99%
“…9 Today, with the large-scale production of CAR cells, cell therapy has arrived in the clinic. Engineered autologous Treg are given to transplant recipients to dampen the allogeneic immune response or even to induce transplant tolerance, 6,7 whereas CAR T cells therapy is successful in cancer treatment. 10 Ellis et al 8 show that human T cells engineered with HLA-specific CARs can also be used as a "human" preclinical model to study the process of allograft rejection in humanized immunodeficient mice without the complication of xGVHD.…”
mentioning
confidence: 99%
“…In this issue of the KI Reports , Schreeb et al. 1 propose a framework of a phase I/IIa clinical trial using Tregs that have been genetically engineered to recognize alloantigen.…”
mentioning
confidence: 99%
“…In this edition of the KI Reports , Katharina Schreeb et al. 1 described the protocol of the STEADFAST study, a first-in-human phase I/IIa multicenter clinical trial using CAR Tregs. It is a multicentric European study with 5 to 6 participating renal transplant centers based in Belgium, The Netherlands, and the United Kingdom.…”
mentioning
confidence: 99%